Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 19, 2021

Medolife Rx reports positive data from Covid-19 drug candidate study

Quanta subsidiary Medolife Rx has reported positive results from a study that assessed the safety and toxicity of a polarised drug candidate to treat Covid-19 patients.

Quanta subsidiary Medolife Rx has reported positive results from a study that assessed the safety and toxicity of a polarised drug candidate to treat Covid-19 patients.

The study was conducted on more than 500 patients in Santo Domingo of the Dominican Republic.

The subjects were administered with the drug Escozine, a polarised solution of the Rhopalurus princeps scorpion peptide owned by Medolife, sublingually four times a day.

After administration, the associated researchers conducted a complete blood count (CBC) of each patient and measured different parameters such as hemoglobin (Hb), hematocrit (HCT) and red blood cells (RBCs) levels.

The assessment did not observe any significant differences before and after administration.

Furthermore, there was no significant change in white blood cells (WBCs), neutrophils, lymphocytes, monocytes, or eosinophils.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The data indicated that the drug candidate is safe and non-toxic.

Medolife CEO Dr Arthur Mikaelian said: “A successful safety study is a pivotal step in the clinical development programme for a new drug candidate and we could not be more enthusiastic about our results.

“While our near-term goal is to work with the Ministry of Environment of The Dominican Republic to bring this drug to market, we are able to use this data in our programmes around the world, including with our submissions to the US Food and Drug Administration.

“While there is significant research that suggests the potential therapeutic benefits of extracted scorpion peptide, when paired with our proprietary polarisation technology that increases efficacy and bioavailability in the body, we believe our product Escozine could be a true breakthrough in the field of medicine with applications in a variety of focus areas and indications.”

In a separate development, Dyadic International, a biotechnology company, announced that it is planning to conduct first-in-human Phase I clinical trial of its vaccine candidate, DYAI-100, in the second half of this year.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU